Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Interobserver variability for the WHO classification of pulmonary carcinoids.

Swarts DR, van Suylen RJ, den Bakker MA, van Oosterhout MF, Thunnissen FB, Volante M, Dingemans AM, Scheltinga MR, Bootsma GP, Pouwels HM, van den Borne BE, Ramaekers FC, Speel EJ.

Am J Surg Pathol. 2014 Oct;38(10):1429-36. doi: 10.1097/PAS.0000000000000300.

PMID:
25046341
2.

Neuroendocrine tumours--challenges in the diagnosis and classification of pulmonary neuroendocrine tumours.

den Bakker MA, Thunnissen FB.

J Clin Pathol. 2013 Oct;66(10):862-9. doi: 10.1136/jclinpath-2012-201310. Epub 2013 May 17. Review.

PMID:
23685279
4.

A similar approach in bracing of adolescent scoliosis and kyphosis with the use of growth itself in Thoracolumbar Lordotic Intervention (TLI).

Van Loon PJ, Roukens M, Thunnissen FB, Munneke J.

Stud Health Technol Inform. 2012;176:68-72.

PMID:
22744460
5.

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.

Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, Thunnissen FB, Heideman DA, de Weger RA, Vink A.

Cell Oncol (Dordr). 2012 Jun;35(3):189-96. doi: 10.1007/s13402-012-0078-4. Epub 2012 Apr 12.

6.

The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules.

van 't Westeinde SC, Horeweg N, Vernhout RM, Groen HJM, Lammers JJ, Weenink C, Nackaerts K, Oudkerk M, Mali W, Thunnissen FB, de Koning HJ, van Klaveren RJ.

Chest. 2012 Aug;142(2):377-384. doi: 10.1378/chest.11-2030.

PMID:
22302298
7.

Pseudomelanosis coli and adenomatous polyps.

Van Weyenberg SJ, Hoentjen F, Thunnissen F, Mulder CJ.

J Gastrointestin Liver Dis. 2011 Sep;20(3):233. No abstract available.

8.

The role of the ¹⁸f-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial.

van't Westeinde SC, de Koning HJ, Thunnissen FB, Oudkerk M, Groen HJ, Lammers JW, Weenink C, Vernhout R, Nackaerts K, Mali W, van Klaveren RJ.

J Thorac Oncol. 2011 Oct;6(10):1704-12. doi: 10.1097/JTO.0b013e3182286d0b.

9.

Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development.

Thunnissen FB, Prinsen C, Hol B, Van der Drift M, Vesin A, Brambilla C, Montuenga L, Field JK; EUELC consortium.

Lung Cancer. 2012 Feb;75(2):156-60. doi: 10.1016/j.lungcan.2011.07.013. Epub 2011 Aug 11.

PMID:
21839537
10.

DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer.

van Boerdonk RA, Sutedja TG, Snijders PJ, Reinen E, Wilting SM, van de Wiel MA, Thunnissen FE, Duin S, Kooi C, Ylstra B, Meijer CJ, Meijer GA, Grünberg K, Daniels JM, Postmus PE, Smit EF, Heideman DA.

Am J Respir Crit Care Med. 2011 Oct 15;184(8):948-56. doi: 10.1164/rccm.201102-0218OC. Epub 2011 Jul 28.

PMID:
21799074
11.

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF.

Eur J Cancer. 2011 Nov;47(17):2603-6. doi: 10.1016/j.ejca.2011.06.046. Epub 2011 Jul 23.

PMID:
21784628
12.

Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome.

Swarts DR, Claessen SM, Jonkers YM, van Suylen RJ, Dingemans AM, de Herder WW, de Krijger RR, Smit EF, Thunnissen FB, Seldenrijk CA, Vink A, Perren A, Ramaekers FC, Speel EJ.

Am J Pathol. 2011 Sep;179(3):1129-37. doi: 10.1016/j.ajpath.2011.05.028. Epub 2011 Jul 16.

13.

Diagnosing peripheral lung cancer: the additional value of the Ras-association domain family 1A gene methylation and Kirsten rat sarcoma 2 viral oncogene homolog mutation analyses in washings in nondiagnostic bronchoscopy.

van der Drift MA, Prinsen CFM, Knuiman GJ, Janssen JP, Dekhuijzen PNR, Thunnissen FBJM.

Chest. 2012 Jan;141(1):169-175. doi: 10.1378/chest.10-2579. Epub 2011 Jun 23.

PMID:
21700687
14.

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.

Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, van Tinteren H, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF, Groen HJ.

Ann Oncol. 2011 Mar;22(3):559-66. doi: 10.1093/annonc/mdq391. Epub 2010 Aug 11.

PMID:
20702788
15.

The clinical value of lymphatic micrometastases in patients with non-small cell lung cancer.

Verhagen AF, Bulten J, Shirango H, Thunnissen FB, van der Drift MA, van der Bruggen W, Tjan-Heijnen VC, van Swieten HA.

J Thorac Oncol. 2010 Aug;5(8):1201-5. doi: 10.1097/JTO.0b013e3181e29ace.

16.

Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability.

den Bakker MA, Willemsen S, Grünberg K, Noorduijn LA, van Oosterhout MF, van Suylen RJ, Timens W, Vrugt B, Wiersma-van Tilburg A, Thunnissen FB.

Histopathology. 2010 Feb;56(3):356-63. doi: 10.1111/j.1365-2559.2010.03486.x.

PMID:
20459535
17.

Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.

Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE.

J Thorac Oncol. 2010 May;5(5):719-20. doi: 10.1097/JTO.0b013e3181d86ebf. No abstract available.

18.

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.

Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF.

Clin Cancer Res. 2010 Jun 1;16(11):3078-87. doi: 10.1158/1078-0432.CCR-09-3033. Epub 2010 Apr 15.

19.

Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease pattern.

van der Veldt AA, Comans EF, Thunnissen FB, Hendrikse NH, Smit EF, van der Hoeven JJ.

Clin Radiol. 2010 Jan;65(1):94-6; author reply 96-7. doi: 10.1016/j.crad.2009.08.011. Epub 2009 Nov 11. No abstract available.

PMID:
20103429
20.

EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration.

Field JK, Liloglou T, Niaz A, Bryan J, Gosney JR, Giles T, Brambilla C, Brambilla E, Vesin A, Timsit JF, Hainaut P, Martinet Y, Vignaud JM, Thunnissen FB, Prinsen C, Snijders PJ, Smit EF, Sozzi G, Roz L, Risch A, Becker HD, Elborn JS, Magee ND, Montuenga LM, Pajares MJ, Lozano MD, O'Byrne KJ, Harrison DJ, Niklinski J, Cassidy A; EUELC Collaborators.

Eur Respir J. 2009 Dec;34(6):1477-86. doi: 10.1183/09031936.00077809.

21.

A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes.

Heideman DA, Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF, Postmus PE, Meijer CJ, Meijer GA, Snijders PJ.

Cell Oncol. 2009;31(5):329-33. doi: 10.3233/CLO-2009-0489.

22.

Acetylcholine receptor pathway and lung cancer.

Thunnissen FB.

J Thorac Oncol. 2009 Aug;4(8):943-6. doi: 10.1097/JTO.0b013e3181ad83fc. Review.

23.

Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.

van der Drift MA, Hol BE, Klaassen CH, Prinsen CF, van Aarssen YA, Donders R, van der Stappen JW, Dekhuijzen PN, van der Heijden HF, Thunnissen FB.

Lung Cancer. 2010 May;68(2):283-7. doi: 10.1016/j.lungcan.2009.06.021. Epub 2009 Jul 25.

PMID:
19632736
24.

A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations.

Kramer D, Thunnissen FB, Gallegos-Ruiz MI, Smit EF, Postmus PE, Meijer CJ, Snijders PJ, Heideman DA.

Cell Oncol. 2009;31(3):161-7. doi: 10.3233/CLO-2009-0466.

25.

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.

Galleges Ruiz MI, Floor K, Steinberg SM, Grünberg K, Thunnissen FB, Belien JA, Meijer GA, Peters GJ, Smit EF, Rodriguez JA, Giaccone G.

Br J Cancer. 2009 Jan 13;100(1):145-52. doi: 10.1038/sj.bjc.6604781. Epub 2008 Dec 2.

26.

Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene.

Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, Thunnissen FB, Wistuba II, Czerniak B, Frenkel E, Roth JA, Liloglou T, Xinarianos G, Field JK, Minna JD, Gazdar AF.

Cancer Res. 2008 Sep 15;68(18):7448-56. doi: 10.1158/0008-5472.CAN-08-0565.

27.

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.

Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR.

Cancer. 2008 Oct 15;113(8):2129-38. doi: 10.1002/cncr.23826.

28.

Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay.

Shivapurkar N, Stastny V, Xie Y, Prinsen C, Frenkel E, Czerniak B, Thunnissen FB, Minna JD, Gazdar AF.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):995-1000. doi: 10.1158/1055-9965.EPI-07-2808.

29.

Forced lordosis on the thoracolumbar junction can correct coronal plane deformity in adolescents with double major curve pattern idiopathic scoliosis.

van Loon PJ, Kühbauch BA, Thunnissen FB.

Spine (Phila Pa 1976). 2008 Apr 1;33(7):797-801. doi: 10.1097/BRS.0b013e3181694ff5.

PMID:
18379408
30.

Can free DNA be detected in sputum of lung cancer patients?

van der Drift MA, Prinsen CF, Hol BE, Bolijn AS, Jeunink MA, Dekhuijzen PN, Thunnissen FB.

Lung Cancer. 2008 Sep;61(3):385-90. doi: 10.1016/j.lungcan.2008.01.007. Epub 2008 Mar 4.

PMID:
18313165
31.

Baseline human papillomavirus status of women with abnormal smears in cervical screening: a 5-year follow-up study in The Netherlands.

Prinsen CF, Fles R, Wijnen-Dubbers CW, de Valk HA, Klaassen CH, Mravunac M, Horrevorts AM, Thunnissen FB.

BJOG. 2007 Aug;114(8):951-7. Epub 2007 Jun 18.

32.

Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria.

Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M.

J Thorac Oncol. 2006 Nov;1(9 Suppl):S13-9.

33.

Risk factors for non-sentinel lymph node metastases in patients with breast cancer. The outcome of a multi-institutional study.

Bolster MJ, Peer PG, Bult P, Thunnissen FB, Schapers RF, Meijer JW, Strobbe LJ, van Berlo CL, Klinkenbijl JH, Beex LV, Wobbes T, Tjan-Heijnen VC.

Ann Surg Oncol. 2007 Jan;14(1):181-9. Epub 2006 Oct 7.

PMID:
17028772
34.

EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer.

Thunnissen FB, Kerr KM, Brambilla E, Comin CE, Franklin WA, Guldhammerskov B, Westra WH, Flieder DB.

Eur Respir J. 2006 Dec;28(6):1186-9. Epub 2006 Aug 9.

35.

A critical appraisal of prognostic and predictive factors for common lung cancers.

Thunnissen FB, Schuurbiers OC, den Bakker MA.

Histopathology. 2006 Jun;48(7):779-86. Review.

PMID:
16722925
36.

Application of a methylation gene panel by quantitative PCR for lung cancers.

Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF.

Cancer Lett. 2007 Mar 8;247(1):56-71. Epub 2006 Apr 27.

37.

Implications of frozen section analyses from bronchial resection margins in NSCLC.

Thunnissen FB, den Bakker MA.

Histopathology. 2005 Dec;47(6):638-40. No abstract available.

PMID:
16324203
38.

Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands?

Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ.

Ann Surg Oncol. 2005 Dec;12(12):1066-72. Epub 2005 Oct 26.

PMID:
16244802
39.

Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer.

Kievit W, Bolster MJ, van der Wilt GJ, Bult P, Thunnissen FB, Meijer J, Strobbe LJ, Klinkenbijl JH, Wobbes T, Adang EM, Beex LV, Tjan-Heijnen VC.

Ann Oncol. 2005 Dec;16(12):1874-81. Epub 2005 Sep 2.

PMID:
16143593
40.

A prospective study of the timing and cost-effectiveness of bronchial washing during bronchoscopy for pulmonary malignant tumors.

van der Drift MA, van der Wilt GJ, Thunnissen FB, Janssen JP.

Chest. 2005 Jul;128(1):394-400.

PMID:
16002962
41.

Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity.

Comhair SA, Xu W, Ghosh S, Thunnissen FB, Almasan A, Calhoun WJ, Janocha AJ, Zheng L, Hazen SL, Erzurum SC.

Am J Pathol. 2005 Mar;166(3):663-74.

42.

Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension.

Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, Thunnissen FB, Farver C, Hazen SL, Jennings C, Dweik RA, Arroliga AC, Erzurum SC.

FASEB J. 2004 Nov;18(14):1746-8. Epub 2004 Sep 13.

PMID:
15364894
43.

Quality control in diagnostic molecular pathology in the Netherlands; proficiency testing for patient identification in tissue samples.

Thunnissen FB, Tilanus MG, Ligtenberg MJ, Nederlof PM, Dinjens WN, Meulemans E, Van den Brule AJ, van Noesel CJ, de Leeuw WJ, Schuuring E; Dutch Pathology Molecular Diagnostic Working Groups.

J Clin Pathol. 2004 Jul;57(7):717-20.

44.

Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.

Vicent S, Garayoa M, López-Picazo JM, Lozano MD, Toledo G, Thunnissen FB, Manzano RG, Montuenga LM.

Clin Cancer Res. 2004 Jun 1;10(11):3639-49.

45.

DNA microarray format for detection and subtyping of human papillomavirus.

Klaassen CH, Prinsen CF, de Valk HA, Horrevorts AM, Jeunink MA, Thunnissen FB.

J Clin Microbiol. 2004 May;42(5):2152-60.

46.

Diagnostic yield of transbronchial histology needle aspiration in patients with mediastinal lymph node enlargement.

Hermens FH, Van Engelenburg TC, Visser FJ, Thunnissen FB, Termeer R, Janssen JP.

Respiration. 2003 Nov-Dec;70(6):631-5.

PMID:
14732795
47.

Sputum examination for early detection of lung cancer.

Thunnissen FB.

J Clin Pathol. 2003 Nov;56(11):805-10. Review.

48.

Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer.

Klaassen CH, Jeunink MA, Prinsen CF, Ruers TJ, Tan AC, Strobbe LJ, Thunnissen FB.

Clin Chem. 2003 Jul;49(7):1185-7. No abstract available.

49.

Microarray as a model for quantitative visualization chemistry.

Prinsen CF, Klaassen CH, Thunnissen FB.

Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):168-73.

PMID:
12778003
50.

Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT.

Somers VA, Thunnissen FB.

Methods Mol Med. 2003;75:305-23. No abstract available.

PMID:
12407749

Supplemental Content

Loading ...
Support Center